FUTURE OF HEALTHCARE
MERU HEALTH | January 18, 2022
Meru Health, the most comprehensive mental health solution in the market with industry-leading outcomes, and Evry Health, a modern business-to-business health insurance company announced today that they will partner on delivering Meru Health's solution to Evry Health's members in Dallas, Texas starting January 2022.
The Meru Health online mental health solution will be embedded as part of Evry Health's tailored wellness plans that come at no cost to the employer or their employees. These specialized, optional wellness solutions provide a wide range of resources, tools and rewards that are different from other health insurance plans, including benefits such as mental health support through Meru Health. Members will be recommended to the program based on pre-screening criteria as well as Evry Health's data analysis.
For example, if Evry Health receives a claim for cancer screening and oncologist claims, this is a flag to proactively loop the member into Meru Health's mental health program and support cycles. The partnership will focus on delivering outcomes-based mental healthcare and it rewards members for following their personalized care pathways. A member who completes Meru Health's 12-week Therapy program can get up to $100 reward for doing so.
"This is a completely new way of delivering mental healthcare and we are proud to partner with Meru Health to together change how the system works," said Chris Gay, Evry Health CEO. "Focusing on outcomes is the way mental healthcare – and healthcare in general – should be delivered now and in the future. We are confident our members will get the best possible value-based care, and see their mental health improve as they go through the Meru Health program."
Incentivizing members to take care of their mental health can lead to major cost savings down the line. According to data from BCBS, people with major depression are on average nearly 30 percent less healthy than those without depression. This decrease in overall health translates into increased costs: a depressed person has $6,390 more healthcare costs than nondepressed people every year.
Evry Health incentivizes participants to focus on better mental health through its voluntary wellness plans. Rewards are deposited to an Evry Health Reward Card that members use like any other credit card.
Meru Health is focused on delivering the best long- and short-term outcomes in the market. After program completion, 75% of people are in depression or anxiety symptom remission and 85% of people show clinically significant improvement, measured on industry standard PHQ-9 (depression) and GAD-7 (anxiety) scales. The Meru Health Program is one of only digital mental health interventions with published research that shows that these treatment gains last 12 months after the end of treatment.
"We could not be more excited to partner Evry Health, who is changing health insurance just like we are transforming mental healthcare. Together we can really deliver patient-centric care that ensures that people prioritize their mental health. Health plans and employers would benefit a lot focusing more on outcomes. The question we should be asking is are people getting better and staying better after the treatment? I believe trailblazers like Evry Health will be a role model in the industry to start focusing more on care outcomes."
Kristian Ranta, the CEO of Meru Health
About Meru Health
Meru Health is setting the new standard in mental healthcare with the most comprehensive online solution that combines licensed therapists and psychiatrists, a smartphone-based treatment program, biofeedback training, anonymous peer support, and habit-changing activities for sleep, nutrition, and more.
The company is committed to evidence-based care and has published groundbreaking clinical outcomes with Stanford, Harvard, and UC Davis that show promising clinical effectiveness and lasting results. Meru Health offers a convenient, accessible, side-effect-free mental health treatment option in contrast to the standard of care in the U.S. today. Meru Health partners with major health insurance providers like Cigna, Humana, and Moda Health, as well as leading businesses that want to provide best-in-class mental health care for their employees or members.
About Evry Health
Headquartered in Dallas, Evry Health is not your standard health plan. We're on a mission to make healthcare affordable, transparent and high quality again by providing expanded benefits at an affordable price, lowering premiums by up to 20%. We're building the health insurance we've always wanted for ourselves, with a high-tech, mobile-first experience focused on helping people live better, healthier lives.
Alkem Laboratories Ltd. | January 13, 2022
Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India.
India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system.
"In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers."
Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd
Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives."
About Alkem Laboratories Ltd
Established in 1973 and headquartered in Mumbai, Alkemis a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.
L2Mtech | February 17, 2021
CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications.
CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications
CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications
CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications
CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications
CE Mark Approval for FlexiTrack 035™, Peripheral Balloon Catheter for Endovascular Applications
Bonn, Germany – L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products:
LimusTrack™ : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the treatment of coronary artery disease, de novo lesions, restenosis lesions.
LomiFlow™ : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease, small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases.
PearlFlow™ : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease, PTA, dilatation of stenotic segments or lesions in peripheral arteries.
PearlFlow NS™ : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial disease, de novo lesions, lesions in femoropopliteal arteries.
FlexiTrack 018™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in femoral, popliteal, tibial arteries.
FlexiTrack 035™ : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial disease, dilatation of lesions in the SFA, femoral arteries.
L2Mtech GmbH Founder and CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to the efficacy and safety of our innovative technology products for Cardiovascular and Endovascular applications.“
We now prepare to commercially launch the products in all markets where the CE Mark is recognized. With introduction of our innovative technology products in markets, we will be able to expand treatment options for the benefit of many millions of patients with coronary and peripheral artery disease around the world.
Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture and commercialization of medical devices that are used by healthcare establishments globally. L2MTech will provide interventional physicians with innovative vascular devices including Drug Eluting Balloon manufactured in Europe.Our Core mission is to build a product portfolio focused on minimally invasive treatment for patients with cardiovascular,endovascular and vascular artery disease. For further information, please visit : L2MTech.de
+49 228 94730761
Graham Healthcare Group | December 21, 2021
Graham Healthcare Group, a leader in homecare, palliative and hospice services, today announced its acquisition of InTeliCare Health Services, a provider of home health services in central Florida. The agreement was finalized on December 15th, 2021, and marks Graham's first expansion into Florida.
Graham will integrate InTeliCare into its Residential Home Health division to accelerate access to personalized home health care throughout Florida. Residential is a leading post-acute home care network serving communities in Michigan, Illinois and Pennsylvania.
Integrating InTeliCare into Residential Home Health will bring together industry-leading, patient-centered home health services to strengthen the continuum of care for patients across central Florida.
"More than one-fifth of Florida's population is over 65, and that number continues to grow. With the baby boomer generation doubling in size and an increase in comorbidities, this is an ideal time for Graham Healthcare Group to begin serving people in the state of Florida in their own homes with high-quality post-acute and end-of-life care."
David Curtis, Chief Executive Officer of Home Health at Graham Healthcare Group
"With the addition of InTeliCare, we're poised for growth as we continue our mission to transform home care and improve patient experiences," Curtis said. "This agreement expands the ability of Graham Healthcare Group to deliver consistent, high-quality care across the spectrum of home health and further strengthens our foundation for success."
Irene Tuttle, InTeliCare Founder and Chief Executive Officer, will serve in an advisory role following the deal's close. Toni Walker, InTeliCare's longstanding Vice President of Operations, will maintain leadership over day-to-day operations.
"We strongly align with Residential's values of care and community," Tuttle said. "This is an extraordinary opportunity to join forces with an organization that shares our employee- and patient-driven approach to care."
"We are confident that the powerful synergies and added strength this partnership creates will continue to elevate the value and experience of post-acute care and advance the continuum of home health care in central Florida," Tuttle added.
Residential Home Health intends to retain InTelicare's workforce and will support them with enhanced operational efficiencies and advanced clinical and technology innovations.
Both Residential Home Health and InTeliCare are known for strong, employee-friendly cultures. Residential has been recognized as a top workplace for 11 consecutive years in the Detroit market and was recognized in the Chicago and St. Louis markets in 2021.
About Graham Healthcare Group
A subsidiary of Graham Holdings Company, Graham Healthcare Group has designed business and technology solutions to drive better care, outcomes and productivity in home health and hospice services for more than 20 years. Itincludes Residential Healthcare Group, Allegheny Health Network-Healthcare @ Home, Mary Free Bed at Home, Clarus, and CSI Pharmacy. Itis deeply committed to radically changing the home care model by putting patients and their families at the top of the paradigm, while enhancing the quality and consistency of healthcare in the most convenient and cost-effective setting possible: at home.
About Residential Home Health
Based in Troy, Michigan, Residential Home Health is a leading provider of home health, palliative and hospice services in Michigan, Illinois and Pennsylvania. Residential is one of the fastest growing home health networks with 2,500 dedicated care professionals.
About InTeliCare Health Services
Based in Boca Raton, InTeliCare is a leading provider of home health services in central Florida. The company has 80 employees serving nearly 300 patients from three offices.